Vaccination with the 13-valent pneumococcal conjugate vaccine (PCV13) followed ≥ 1 year by the 23-valent pneumococcal polysaccharide vaccine (PPSV23) is recommended for immunocompetent adults ≥ 65 years of age in the United States. This study assessed antipneumococcal opsonophagocytic activity (OPA) geometric mean titers (GMTs) to PCV13 in PPSV23-naive and PPSV23-preimmunized adults 1 year after a second vaccine dose. Two parent studies were conducted previously: (1) PPSV23 vaccine–naive subjects (60–64 years of age at enrollment) received PCV13 followed by PCV13 or PPSV23 1 year later or PPSV23 followed by PCV13 1 year later; and (2) subjects (≥ 70 years of age at enrollment) vaccinated with PPSV23 ≥ 5 years before study entry received PCV13 or PPSV23 followed by PCV13 1 year later. Overall, 962 subjects (PPSV23-naive, n = 519; PPSV23-preimmunized, n = 443) who received both vaccinations in the parent studies were enrolled. Numerically higher OPA GMTs persisted for at least 1 year after administration of PCV13 as the initial vaccine (PCV13/PPSV23 or PCV13/PCV13) compared with those who received PPSV23 either 1 or 5 years prior (PPSV23/PCV13). This impairment in antibody responses to subsequent PCV13 vaccination produced by initial PPSV23 vaccination persisted for at least 1 year. OPA GMTs were numerically higher for most serotypes 1 year after 2 doses of PCV13 compared with 1 year after the first PCV13 dose. These data suggest PCV13 should be given first if both vaccines are to be administered, higher immune responses were achieved when PCV13 was given first and persisted at least 1 year (ClinicalTrials.gov Identifier: NCT01025336).
|Number of pages||9|
|Journal||Human Vaccines and Immunotherapeutics|
|State||Published - Mar 4 2019|
Bibliographical noteFunding Information:
This study was funded by Wyeth Vaccines Research, which was acquired by Pfizer Inc in October 2009. After 2009, funding for this study was provided by Pfizer Inc. Editorial support was provided by Daniel E. McCallus, PhD, and Susan DeRocco, PhD, of Complete Healthcare Communications, LLC (West Chester, PA), a CHC Group company, and was funded by Pfizer Inc. The University of Kentucky ID Clinical Research Team was Elizabeth Plummer, Dana Hargis, Heather Flynn, Debra Plummer, Malissia VanHook, Connie Geradot, and the UK-CCTS Clinic.
Editorial support was provided by Daniel E. McCallus, PhD, and Susan DeRocco, PhD, of Complete Healthcare Communications, LLC (West Chester, PA), a CHC Group company, and was funded by Pfizer Inc. The University of Kentucky ID Clinical Research Team was Elizabeth Plummer, Dana Hargis, Heather Flynn, Debra Plummer, Malissia VanHook, Connie Geradot, and the UK-CCTS Clinic.
© 2018, © 2018 The Author(s). Published with license by Taylor & Francis Group, LLC.
- 13-valent pneumococcal conjugate vaccine
- Antibody persistence
- clinical studies
- opsonophagocytic activity
ASJC Scopus subject areas
- Immunology and Allergy